Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IG3018
- Development stage
- Phase 2
- Lead developer
- Intellia Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IG3018 is an oral small molecule drug under development by Intelligem Therapeutics Australia for the treatment of hyperuricemia, including in patients with or without chronic kidney disease. It belongs to the class of uricosurics, which are drugs that increase the excretion of uric acid in urine to lower blood uric acid levels. The precise mechanism of action for IG3018 has not been defined publicly. As of early 2025, it is being evaluated in phase I/II clinical trials for safety, tolerability, pharmacokinetics (PK), and efficacy in subjects with hyperuricemia and those with advanced predialysis chronic kidney disease (CKD stages 3a–4)[1][2][3][4][5][6][7].
- Other names
- IG3018IG-3018IG 3018
Beyond the preview
Go deeper on IG3018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IG3018.